journal
MENU ▼
Read by QxMD icon Read
search

Clinical Colorectal Cancer

journal
https://www.readbyqxmd.com/read/28284575/mfolfox6-plus-panitumumab-versus-5-fu-lv-plus-panitumumab-after-six-cycles-of-frontline-mfolfox6-plus-panitumumab-a-randomized-phase-ii-study-of-patients-with-unresectable-or-advanced-recurrent-ras-wild-type-colorectal-carcinoma-sapphire-study-design-and%C3%A2-rationale
#1
Naoki Nagata, Hideyuki Mishima, Shuichi Kurosawa, Koji Oba, Junichi Sakamoto
BACKGROUND: In Japan, oxaliplatin (OXA)/5-fluorouracil (5-FU)/leucovorin (LV)-the mFOLFOX6 regimen-is the most frequently used first-line chemotherapy backbone for metastatic colorectal cancer. However, peripheral nerve disorders caused by OXA during mFOLFOX6 therapy can decrease patients' quality of life. OXA can be safely discontinued from a FOLFOX regimen after 6 cycles during first-line therapy. Also, for patients who discontinue OXA without having experienced peripheral nerve disorders, reintroducing OXA in the later stages of treatment could remain an option...
March 1, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28242162/molecular-screening-for-lynch-syndrome-in-young-patients-with-colorectal-adenomas
#2
Robin B Mendelsohn, Keri Herzog, Jinru Shia, Nadiyah Rahaman, Zsofia K Stadler, Moshe Shike
BACKGROUND: The frequency of mismatch repair (MMR) deficiency (dMMR) in patients < 50 years with adenomas without a known germline mutation is unknown. Our aim was to define the frequency of dMMRs in adenomas from patients aged < 50 years. PATIENTS AND METHODS: We identified all patients aged 18 to 49 years who had undergone colonoscopy at Memorial Sloan Kettering Cancer Center from 2008 to 2013 and were identified as having tubular, villous, or tubulovillous adenomas on pathology...
February 2, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28284574/comparison-of-5-fu-based-and-capecitabine-based-neoadjuvant-chemoradiotherapy-in-patients-with-rectal-cancer-a-meta-analysis
#3
Xiang-Cai Zou, Qiwen Wang, Jimin Zhang
INTRODUCTION: The inconvenience of using infusion therapies resulted in the development of capecitabine (CA), an oral fluoropyrimidine. In this meta-analysis, we evaluated 10 studies that compared the efficacy and safety of an oral CA-based regimen with those of a continuous infusion 5-fluorouracil (5-FU) regimen for neoadjuvant chemoradiotherapy in patients with rectal cancer. MATERIALS AND METHODS: The databases searched included Medline, Cochrane, EMBASE, and Google Scholar (until August 31, 2016)...
January 25, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28242161/adherence-dosing-and-managing-toxicities-with-trifluridine-tipiracil-tas-102
#4
REVIEW
James J Lee, Edward Chu
Trifluridine/tipiracil (TAS-102) is a new oral combination therapy approved by the US Food and Drug Administration for the treatment of patients with metastatic colorectal cancer who are refractory to or intolerant of standard chemotherapy. This agent consists of a thymidine-based nucleoside analogue (trifluridine) and a thymidine phosphorylase inhibitor (tipiracil), which is included to reduce the degradative breakdown of trifluridine. In the phase III Randomized, double-blind, phase III Study of TAS-102 plus best supportive care [BSC] versus placebo plus BSC in patients with metastatic colorectal cancer [CRC] refractory to standard chemotherapies (RECOURSE) trial, trifluridine/tipiracil showed significant improvement in overall survival compared with placebo...
January 25, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28237538/the-identifications-and-clinical-implications-of-cancer-stem-cells-in-colorectal-cancer
#5
REVIEW
S M Riajul Wahab, Farhadul Islam, Vinod Gopalan, Alfred King-Yin Lam
Cancer stem cells (CSCs) are cancer cells that are responsible for initiation, progression, metastasis, and recurrence in cancer. The aim of this review was to analyze the markers for identifying of CSCs in colorectal carcinoma, as well as the prognostic and therapeutic implications of these markers in the cancer. CSCs are insensitive to the current drug regimens. In colorectal carcinoma, markers, including Nanog, Oct-4, SOX-2, Lgr-5, CD133, CD24, CD29, ALDH1, EpCAM, CD44, CD166, and CD26, are commonly used for the identification and isolation of CSCs...
January 25, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28223103/her2-amplification-and-cetuximab-efficacy-in-patients-with-metastatic-colorectal-cancer-harboring-wild-type-ras-and-braf
#6
Jae Ho Jeong, Jihun Kim, Yong Sang Hong, Dalyong Kim, Jeong Eun Kim, Sun Young Kim, Kyu-Pyo Kim, Young-Kwang Yoon, Deokhoon Kim, Sung-Min Chun, Yangsoon Park, Se Jin Jang, Tae Won Kim
BACKGROUND: Cetuximab has shown clinical benefit in patients with metastatic colorectal cancer (mCRC) harboring wild-type RAS. Human epidermal growth factor receptor 2 (HER2) amplification may be a mechanism of cetuximab resistance. We evaluated the association between HER2 amplification and cetuximab efficacy in patients with mCRC harboring wild-type RAS and BRAF. PATIENTS AND METHODS: Between December 2003 and June 2013, we identified 142 patients with mCRC whose tumors harbored both wild-type exons 2, 3, and 4 in KRAS and NRAS, and wild-type exon 15 in BRAF using high throughput sequencing (OncoMap version 4...
January 25, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28216247/oncologic-outcomes-of-oral-adjuvant-chemotherapy-regimens-in-stage-iii-colon-cancer-tegafur-uracil-plus-leucovorin-versus-capecitabine
#7
Jo Tashiro, Shigeki Yamaguchi, Toshimasa Ishii, Hiroka Kondo, Kiyoka Hara, Hiroki Shimizu, Kenichi Takemoto, Asami Suzuki
INTRODUCTION: Although several major trials of treatment for stage III colon cancer have been reported, no study has compared oral adjuvant chemotherapy regimens using tegafur-uracil in combination with leucovorin (UFT/LV) and capecitabine (CAPE) alone. This study compared the oncologic outcomes of treatment with these 2 oral regimens. PATIENTS AND METHODS: Records of patients with stage III colon cancer who underwent curative surgery and adjuvant chemotherapy from April 2007 and September 2014 were retrospectively reviewed...
January 25, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28216246/effect-of-kras-and-braf-mutations-on-survival-of-metastatic-colorectal-cancer-after-liver-resection-a-systematic-review-and-meta-analysis
#8
Federica Tosi, Elena Magni, Alessio Amatu, Gianluca Mauri, Katia Bencardino, Mauro Truini, Silvio Veronese, Luciano De Carlis, Giovanni Ferrari, Michele Nichelatti, Andrea Sartore-Bianchi, Salvatore Siena
BACKGROUND: The purpose of the study was to evaluate whether the mutational status of Kirsten rat sarcoma viral oncogene homolog (KRAS) or b-viral oncogene homolog B1 (BRAF) could be an independent prognostic factor in the subset of patients with colorectal cancer liver metastases (CRLM) who undergo complete liver resection. MATERIALS AND METHODS: A systematic literature review was performed to identify articles reporting relapse-free survival (RFS) and/or overall survival (OS) of patients who underwent complete liver resection for CRLM, stratified according to KRAS and BRAF mutational status...
January 25, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28209483/a-new-size-based-platform-for-circulating-tumor-cell-detection-in-colorectal-cancer-patients
#9
Bo Young Oh, Jhingook Kim, Woo Yong Lee, Hee Cheol Kim
BACKGROUND: Circulating tumor cells (CTCs) might play a significant role in cancer progression and metastasis. However, the ability to detect CTCs is limited, especially in cells undergoing epithelial-mesenchymal transition. In this study, we evaluated a new size-based CTC detection platform and its clinical efficacy in colorectal cancer. PATIENTS AND METHODS: Blood samples were obtained from 76 patients with colorectal cancer and 20 healthy control subjects for CTC analysis...
January 25, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28209482/effectiveness-of-a-tailored-anterior-saturation-band-in-the-improvement-of-the-image-quality-of%C3%A2-pelvic-magnetic-resonance-for-assessing-rectal%C3%A2-cancer
#10
Chen-Chang Lee, Po-Chou Chen, Hong-Hwa Chen, Chung-Cheng Huang, Li-Han Lin, Shu-Hang Ng, Min-Chi Chen, Sheung-Fat Ko
PURPOSE: We sought to test the effectiveness of the application of a tailored anterior saturation band (ASB) to improve the image quality of pelvic magnetic resonance imaging (MRI) for assessing rectal cancer. METHODS: A total of 165 patients with MRI assessment of rectal cancer between 2013 and 2015 were included. The image quality scores (4-point scale: 1, nondiagnostic through 4, excellent) of MRI without and with tailored ASBs were compared. Sensitivity, specificity, positive and negative predictive values, and accuracy of pelvic MRIs with and without a tailored ASB for T-staging in 65 patients with direct surgery and 67 patients with chemoradiotherapy before surgery were evaluated...
January 25, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28237539/rationale-for-and-design-of-the-paradigm-study-randomized-phase-iii-study-of-mfolfox6-plus-bevacizumab-or-panitumumab-in-chemotherapy-na%C3%A3-ve-patients-with-ras-kras-nras-wild-type-metastatic-colorectal%C3%A2-cancer
#11
Takayuki Yoshino, Hiroyuki Uetake, Katsuya Tsuchihara, Kohei Shitara, Kentaro Yamazaki, Eiji Oki, Takeo Sato, Takeshi Naitoh, Yoshito Komatsu, Takeshi Kato, Kazunori Yamanaka, Kouji Iwasaki, Jumpei Soeda, Masamitsu Hihara, Takeharu Yamanaka, Atsushi Ochiai, Kei Muro
BACKGROUND: It remains unclear whether an anti-VEGF or anti-EGFR antibody with standard doublet chemotherapy is the optimal first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer (mCRC). Here we outline the PARADIGM study (NCT02394795), designed to evaluate the superiority of panitumumab over bevacizumab, in combination with oxaliplatin/5-fluorouracil/leucovorin (mFOLFOX6) in patients with RAS wild-type chemotherapy-naïve mCRC. PATIENTS AND METHODS: Eligible patients are aged 20 to 79 years with an ECOG performance status of 0-1 and histologically/cytologically confirmed RAS wild-type mCRC...
January 24, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28254356/reviewing-the-management-of-obstructive-left-colon-cancer-assessing-the-feasibility-of-the-one-stage-resection-and-anastomosis-after-intraoperative-colonic-irrigation
#12
Gavish Kumar Awotar, Guoxin Guan, Wei Sun, Hongliang Yu, Ming Zhu, Xinye Cui, Jie Liu, Jiaxi Chen, Baoshun Yang, Jianyu Lin, Zeyong Deng, Jianwei Luo, Chen Wang, Osman Abdifatah Nur, Panjak Dhiman, Pixu Liu, Fuwen Luo
BACKGROUND: The management of obstructive left colon cancer (OLCC) remains debatable with the single-stage procedure of primary colonic anastomosis after cancer resection and on-table intracolonic lavage now being supported. PATIENTS AND METHODS: Patients with acute OLCC who were admitted between January 2008 and January 2015 were distributed into 5 different groups. Group ICI underwent emergency laparotomy for primary anastomosis following colonic resection and intraoperative colonic lavage; Group HP underwent emergency Hartmann's Procedure; Group CON consisted of patients treated by conservative management with subsequent elective open cancer resection; Group COL were colostomy patients; and Group INT consisted of patients who had interventional radiology followed by open elective colon cancer resection...
January 18, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28089507/gastrointestinal-perforation-and-fistula-formation-in-5-patients-with-colorectal-cancer-during-treatment-with-regorafenib
#13
Ayako Doi, Yasutoshi Kuboki, Kohei Shitara, Shota Fukuoka, Hideaki Bando, Wataru Okamoto, Takashi Kojima, Toshihiko Doi, Atsushi Ohtsu, Takayuki Yoshino
No abstract text is available yet for this article.
December 28, 2016: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/27600984/toward-a-molecular-classification-of-synchronous-colorectal-cancer-clinical-and-molecular-characterization
#14
María Arriba, Ricardo Sánchez, Daniel Rueda, Laura Gómez, Juan L García, Yolanda Rodríguez, José Antonio Pajares, Jessica Pérez, Miguel Urioste, Rogelio González Sarmiento, José Perea
BACKGROUND: Two or more primary colorectal tumors coexisting at the time of diagnosis are considered to be synchronous tumors. It is estimated that synchronous colorectal cancer (SCRC) only accounts for 1.1% to 8.1% of all colorectal cancers (CRCs), and its molecular basis is still poorly understood. PATIENTS AND METHODS: We evaluated the microsatellite instability (MSI) and the CpG island methylator phenotype (CIMP) statuses in a series of 49 patients (98 tumors) diagnosed with sporadic SCRC at the 12 de Octubre University Hospital with the aim of improving the molecular characterization of this type of tumor...
March 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/27600983/prospective-evaluation-of-a-12-gene-assay-on-patient-treatment-decisions-and-physician-confidence-in-mismatch-repair-proficient-stage-iia-colon-cancer
#15
Lindsay A Renfro, Nan Zhang, Margarita Lopatin, Calvin Chao, Steven R Alberts
BACKGROUND: The Oncotype DX colon cancer assay is a validated predictor of recurrence risk in patients with resected stage II colon cancer. We previously reported that Oncotype DX led to a change in treatment recommendations for 45% of patients with T3 mismatch repair proficient (MMR-P) stage II tumors in a prospective study. In the present study, we report the assay's influence on patient treatment decisions, physician confidence, concordance between physicians and patients, and patient decisional conflict...
March 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/27576095/the-role-of-aspirin-as-antitumoral-agent-for-heavily-pretreated-patients-with-metastatic-colorectal-cancer-receiving-capecitabine-monotherapy
#16
Riccardo Giampieri, Angelo Restivo, Valeria Pusceddu, Michela Del Prete, Elena Maccaroni, Alessandro Bittoni, Luca Faloppi, Kalliopi Andrikou, Maristella Bianconi, Francesco Cabras, Rossana Berardi, Luigi Zorcolo, Francesco Scintu, Stefano Cascinu, Mario Scartozzi
BACKGROUND: The potential clinical impact of aspirin use beyond its canonical indications is a novel matter of scientific debate. In patients with metastatic colorectal cancer failing all available options, regorafenib and TAS 102 represent the only chance of treatment. Although effective, these therapeutic options bring along a not-negligible burden in terms of economic costs and toxicity. In this setting, the indication to use aspirin in combination with chemotherapy would potentially represent a medical revolution under the economic and toxicity profile...
March 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/27528514/new-generation-high-definition-colonoscopes-increase-adenoma-detection-when-screening-a-moderate-risk-population-for-colorectal-cancer
#17
Ashley Bond, Paul O'Toole, Gareth Fisher, Sreedhar Subramanian, Neil Haslam, Chris Probert, Trevor Cox, Sanchoy Sarkar
BACKGROUND AND AIM: Adenoma detection rate (ADR) is the most important quality indicator for screening colonoscopy, due to its association with colorectal cancer outcomes. As a result, a number of techniques and technologies have been proposed that have the potential to improve ADR. The aim of this study was to assess the potential impact of new-generation high-definition (HD) colonoscopy on ADR within the Bowel Cancer Screening Programme (BCSP). METHOD: This was a retrospective single-center observational study in patients undergoing an index screening colonoscopy...
March 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/27522627/lung-metastases-treated-with-stereotactic-ablative-radiation-therapy-in-oligometastatic-colorectal-cancer-patients-outcomes-and-prognostic-factors-after-long-term-follow-up
#18
Linda Agolli, Stefano Bracci, Luca Nicosia, Maurizio Valeriani, Vitaliana De Sanctis, Mattia Falchetto Osti
BACKGROUND: We evaluated a series of oligometastatic colorectal cancer (CRC) patients treated with stereotactic ablative body radiotherapy (SABR) delivered in all active lung metastases. PATIENTS AND METHODS: Forty-four patients with 69 lung metastases were treated with SABR. Eleven patients presented with other sites of metastases before stereotactic body radiotherapy (SBRT), even though they had controlled/cured systemic disease. RESULTS: The median follow-up was 36 months...
March 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/27522626/neutropenia-as-a-predictive-factor-in-metastatic-colorectal-cancer-treated-with-tas-102
#19
Satoshi Hamauchi, Kentaro Yamazaki, Toshiki Masuishi, Yosuke Kito, Azusa Komori, Takahiro Tsushima, Yukiya Narita, Akiko Todaka, Makoto Ishihara, Tomoya Yokota, Tsutomu Tanaka, Nozomu Machida, Shigenori Kadowaki, Akira Fukutomi, Takashi Ura, Yusuke Onozawa, Masashi Ando, Masahiro Tajika, Kei Muro, Hirofumi Yasui, Keita Mori, Hiroya Taniguchi
BACKGROUND: TAS-102 significantly improves overall survival in patients with metastatic colorectal cancer. The most common treatment-related adverse event of TAS-102 is bone marrow suppression, which leads to neutropenia. The potential predictive value of neutropenia caused by cytotoxic drugs has been reported in various types of cancer. METHODS: We retrospectively analyzed 95 consecutive patients with metastatic colorectal cancer who received TAS-102 at 2 Japanese institutions between May 2014 and May 2015...
March 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/27515842/safety-and-efficacy-of-a-modified-flox-adjuvant-regimen-for-patients-with-stage-iii-colorectal-cancer-treated-in-the-community
#20
Bruno Mendonça Protásio, Adriana Matutino, Liana Valente Lage, Iuri Santana, Ricardo Ramos, Jorge Sabbaga, Fernanda Capareli, Daniel Saragiotto, Rachel Riechelmann, Paulo M Hoff
BACKGROUND: The efficacy and safety of the combination of a fluoropyrimidine with oxaliplatin for patients with stage III colorectal cancer (CRC) have been evaluated in selected patients who took part in clinical trials. We evaluated the outcomes of FLOX (bolus fluorouracil [5-FU] combined with oxaliplatin) in patients with resected stage III CRC treated in the community in a large cancer center. PATIENTS AND METHODS: We performed a retrospective unicenter cohort study of all consecutive stage III CRC patients who received adjuvant chemotherapy with an mFLOX (modified FLOX) regimen...
March 2017: Clinical Colorectal Cancer
journal
journal
39741
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"